Detalles de la búsqueda
1.
Genomics to select treatment for patients with metastatic breast cancer.
Nature
; 610(7931): 343-348, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36071165
2.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37256976
3.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582092
4.
Author Correction: Genomic characterization of metastatic breast cancers.
Nature
; 572(7767): E7, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31308536
5.
Genomic characterization of metastatic breast cancers.
Nature
; 569(7757): 560-564, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31118521
6.
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.
Br J Cancer
; 130(4): 613-619, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38182687
7.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 402(10411): 1423-1433, 2023 10 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37633306
8.
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
Oncologist
; 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38748596
9.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33882206
10.
Baseline quality of life and chemotherapy toxicities in patients with early breast cancer.
Cancer
; 129(7): 1085-1095, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36642837
11.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239405
12.
Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution.
Breast Cancer Res Treat
; 198(3): 463-474, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36790573
13.
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Breast Cancer Res Treat
; 199(2): 371-379, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36988749
14.
Investigating the clinical impact of dose-banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study.
Br J Clin Pharmacol
; 89(7): 2283-2294, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36854898
15.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 23(11): 1367-1377, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36183733
16.
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 191(1): 191-207, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34687411
17.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
Future Oncol
; 18(33): 3677-3688, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300423
18.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019819
19.
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Breast Cancer Res
; 23(1): 61, 2021 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34039396
20.
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study.
Breast Cancer Res
; 23(1): 9, 2021 01 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33468209